Quality of ambulatory prevention and treatment of cardiovascular disease and its complications among Туре 2 diabetes mellitus patients

Aim. To evaluate the real-world clinical practice implementation of modern international and national recommendations on primary and secondary prevention and pharmacotherapy of cardiovascular disease (CVD) among patients with Type 2 diabetes mellitus (DM-2) in one administrative area of Moscow City (2004-2006).

Material and methods. Cross-sectional retrospective analysis of ambulatory medical card data was performed among 1146 DM-2 patients attending one out of three Moscow City South-West Area policlinics (2004-2006). Quality of primary and secondary prevention and pharmacotherapy was assessed by compliance with modern international and national standards. The following data from ambulatory medical cards were analyzed: general information on the patient, main risk factors (RFs), comorbidities, instrumental and laboratory tests and their results, number of hospitalizations and sick-leaves, administered therapy.

Results. Ambulatory cards contained inadequate information on RFs and recommendations on RF correction. Alcohol consumption and smoking were mentioned only in 0,53 % and 6,19 % of the cases, respectively. Recommendations on reducing alcohol consumption were recorded for 0,70 %, smoking cessation - for 1,83 %, and salt intake reduction - for 2,44 %. Body weight control was recommended in 1,05 % of the cases only, despite overweight and obesity prevalence of 30 % and >45 %, respectively. The levels of blood pressure (BP), lipids, fasting glucose, glycated hemoglobin (HbAlc) were higher than respective target levels stated in national and international recommendations. Target level of BP was achieved in 4,36 % of DM-2 patients, low-density lipoprotein cholesterol - in 18,35 %, fasting glucose - in 27,67 %, and HbAlc - in 24,80 %.

Conclusion. Real-world clinical practice of ambulatory treatment of DM-2 patients was not consistent with modern international and national standards of CVD prevention and therapy.

1. Дедов И.И., Фадеев В.В. Введение в диабетологию. Москва 1998; 1518 с.

2. Дедов И.И., Шестакова М. В. Алгоритмы специализированной помощи больным сахарным диабетом. Москва "Медиа Сфера" 2006; 104 с.

3. Исакова М.Р., Кондратьева Л.В. Пути коррекции патогенетических звеньев при сахарном диабете 2 типа: препараты сульфонилмочевины и бигуаниды. РМЖ. Раздел: Клин фармак. Антиб. Соц-знач забол 2007; 15(22): 1630-5.

4. Мычка В.Б., Горностаев И.Е., Чазова И.Е. Сердечно-сосудистые осложнения сахарного диабета 2 типа. Кардиология 2002; 4: 73-7.

5. Albert CM, Cliae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003; 107: 2096-101.

6. ADA: Clinical practice recommendations 2007. Diabetes Care 2007; 30 (Suppl. 1): S4-11.

7. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.

8. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention in coronary heart disease, principal results. Eur Heart J 1997; 18: 1569-82.

9. Haffher SM, Lehto S, Ronnemma T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.

10. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Intern Diabetes Feder 2005; 82.

11. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Inter Med 1991; 151: 1141-7.

12. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial research Group. JAMA 1982; 248: 1465-77.

13. Pyorala K, Lechto S, DeBacker G, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Finding from the EUROASPIRE I and II. The Diabetologia 2004; 3: 125-42.

14. Rodriguez-Macas Leocadio, Castro Maria, Manzarbeitia Jorge. Cardiovascular Risk and Diabetes in Old People. Br J Diabetes Vase Dis 2005; 5(1): 7-11.

15. Ryden L, Chairperson C, Standi E, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.